Sorafenib-resistant hepatocellular carcinoma stratified by phosphorylated ERK activates PD-1 immune checkpoint

Sorafenib is a multikinase inhibitor approved as the first line treatment for late stage hepatocellular carcinoma (HCC). Due to its significant variation in clinical benefits among patients, defining prognostic biomarkers for sorafenib sensitivity in HCC would allow targeted treatment. Phosphorylate...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Chen, Jiang, Ji, Tong, Zhao, Jie, Li, Gaofeng, Zhang, Jian, Jin, Renan, Liu, Jinghua, Liu, Xiaolong, Liang, Xiao, Huang, Diyu, Xie, Anyong, Lin, Hui, Cang, Yong, Cai, Xiujun
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2016
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5173058/
https://ncbi.nlm.nih.gov/pubmed/27129180
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.8978
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados